Moderna (MRNA) Stock Forecast & Price Target

Compare

17,820 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MRNA Analyst Ratings

Hold

3 Buy

13 Hold

4 Sell

Based on 20 analysts giving stock ratings to

Moderna

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MRNA Stock 12 Month Forecast

Average Price Target

$38.65

▲(30.44% Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $38.65 with a high forecast of $198.00 and a low forecast of $17.00. The average price target represents a 30.44% change from the last price of $29.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","199":"$199","61.75":"$61.8","107.5":"$107.5","153.25":"$153.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":198,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$198.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,61.75,107.5,153.25,199],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,37.5323076923077,50.90461538461538,64.27692307692308,77.64923076923077,91.02153846153846,104.39384615384616,117.76615384615386,131.13846153846154,144.51076923076923,157.8830769230769,171.25538461538463,184.6276923076923,{"y":198,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,25.274615384615384,26.38923076923077,27.503846153846155,28.61846153846154,29.733076923076922,30.847692307692306,31.962307692307693,33.07692307692308,34.19153846153846,35.30615384615385,36.42076923076923,37.535384615384615,{"y":38.65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,23.60923076923077,23.05846153846154,22.50769230769231,21.956923076923076,21.406153846153845,20.855384615384615,20.304615384615385,19.753846153846155,19.20307692307692,18.652307692307694,18.10153846153846,17.55076923076923,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.26,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.42,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":30.96,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.03,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":28.69,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.19,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.6,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.16,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":24.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 49, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$198.00

Average Price Target$38.65

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Tsai

Jefferies

$30

Hold

1.25%

Upside

Initiated

12/11/25

Moderna's Future: Balancing Growth Potential and Uncertainty with a Hold Rating

Salveen Richter

Goldman Sachs

$33

Hold

11.37%

Upside

Reiterated

12/08/25

Moderna's Growth Prospects: Balancing Revenue Potential and Legal Challenges

Edward Tenthoff

Piper Sandler

$63

Buy

112.62%

Upside

Reiterated

12/03/25

Moderna (MRNA) Gets a Buy from Piper Sandler

Courtney Breen

Bernstein

$25

Hold

-15.63%

Downside

Assigned

12/02/25

Moderna (MRNA) Gets a Hold from Bernstein

Harry Gillis

Berenberg Bank

$28→$26

Hold

-12.25%

Downside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Myles Minter

William Blair

―

Hold

―

Reiterated

11/21/25

Cautious Outlook on Moderna: Hold Rating Amid Breakeven Challenges and Pipeline Prospects

Cory Kasimov

Evercore ISI

$28

Hold

-5.50%

Downside

Reiterated

11/21/25

Evercore ISI Remains a Hold on Moderna (MRNA)

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/21/25

Moderna's Strategic Shift and Financial Outlook: A Hold Rating Amid Cautious Optimism

Terence Flynn

Morgan Stanley

$30

Hold

1.25%

Upside

Reiterated

11/21/25

Moderna's Ambitious Growth Plans and Financial Complexities Lead to Hold RatingWe model 70% POS and risk-adjusted sales of $1.9bn in 2028. (3) mRNA-1403 (norovirus): The ongoing Ph3 study has not accrued sufficient cases and has begun enrolling a second Northern Hemisphere season for additional accruals; interim analysis is expected in 2026. In addition, MRNA commented that a cohort is built into the study for the DSMB to conduct a futility analysis later in 2026. (4) mRESVIA (RSV): 12-month revaccination study 302 (part C) and 24-month revaccination study 301 (part B) met pre-specified non-inferiority criteria for both time points ( Exhibit 4 , Exhibit 5 ). Morgan Stanley & Co. LLC Terence C Flynn, Ph.D.

Mani Foroohar

Leerink Partners

$12→$18

Sell

-39.25%

Downside

Reiterated

11/21/25

Cautious Outlook on Moderna: Debt Reliance and Modest Growth Amidst Legal Challenges

David Dai

UBS

$40

Buy

35.00%

Upside

Reiterated

11/21/25

Moderna's Strategic Growth and Financial Outlook: Buy Rating Affirmed by Analyst David Dai

Gena Wang

Barclays

$25

Hold

-15.63%

Downside

Reiterated

11/21/25

Moderna (MRNA) Gets a Hold from Barclays

Geoff Meacham

Citi

$28

Hold

-5.50%

Downside

Reiterated

11/20/25

Cautious Hold on Moderna Amid Strategic Pipeline Shift and Financial Uncertainty

Luca Issi

RBC Capital

$28→$25

Hold

-15.63%

Downside

Reiterated

11/20/25

RBC Capital Reaffirms Their Hold Rating on Moderna (MRNA)

Alexandria Hammond

Wolfe Research

$16→$17

Sell

-42.63%

Downside

Reiterated

11/20/25

Moderna price target raised to $17 from $16 at Wolfe ResearchModerna price target raised to $17 from $16 at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Tsai

Jefferies

$30

Hold

1.25%

Upside

Initiated

12/11/25

Moderna's Future: Balancing Growth Potential and Uncertainty with a Hold Rating

Salveen Richter

Goldman Sachs

$33

Hold

11.37%

Upside

Reiterated

12/08/25

Moderna's Growth Prospects: Balancing Revenue Potential and Legal Challenges

Edward Tenthoff

Piper Sandler

$63

Buy

112.62%

Upside

Reiterated

12/03/25

Moderna (MRNA) Gets a Buy from Piper Sandler

Courtney Breen

Bernstein

$25

Hold

-15.63%

Downside

Assigned

12/02/25

Moderna (MRNA) Gets a Hold from Bernstein

Harry Gillis

Berenberg Bank

$28→$26

Hold

-12.25%

Downside

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: Moderna (NASDAQ: MRNA) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)

Myles Minter

William Blair

―

Hold

―

Reiterated

11/21/25

Cautious Outlook on Moderna: Hold Rating Amid Breakeven Challenges and Pipeline Prospects

Cory Kasimov

Evercore ISI

$28

Hold

-5.50%

Downside

Reiterated

11/21/25

Evercore ISI Remains a Hold on Moderna (MRNA)

Joseph Stringer

Needham

―

Hold

―

Reiterated

11/21/25

Moderna's Strategic Shift and Financial Outlook: A Hold Rating Amid Cautious Optimism

Terence Flynn

Morgan Stanley

$30

Hold

1.25%

Upside

Reiterated

11/21/25

Mani Foroohar

Leerink Partners

$12→$18

Sell

-39.25%

Downside

Reiterated

11/21/25

Cautious Outlook on Moderna: Debt Reliance and Modest Growth Amidst Legal Challenges

David Dai

UBS

$40

Buy

35.00%

Upside

Reiterated

11/21/25

Moderna's Strategic Growth and Financial Outlook: Buy Rating Affirmed by Analyst David Dai

Gena Wang

Barclays

$25

Hold

-15.63%

Downside

Reiterated

11/21/25

Moderna (MRNA) Gets a Hold from Barclays

Geoff Meacham

Citi

$28

Hold

-5.50%

Downside

Reiterated

11/20/25

Cautious Hold on Moderna Amid Strategic Pipeline Shift and Financial Uncertainty

Luca Issi

RBC Capital

$28→$25

Hold

-15.63%

Downside

Reiterated

11/20/25

RBC Capital Reaffirms Their Hold Rating on Moderna (MRNA)

Alexandria Hammond

Wolfe Research

$16→$17

Sell

-42.63%

Downside

Reiterated

11/20/25

Moderna price target raised to $17 from $16 at Wolfe ResearchModerna price target raised to $17 from $16 at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Moderna

1 Month

xxx

Success Rate

29/47 ratings generated profit

Average Return

+0.62%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 61.70% of your transactions generating a profit, with an average return of +0.62% per trade.

3 Months

xxx

Success Rate

29/47 ratings generated profit

Average Return

-5.49%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 61.70% of your transactions generating a profit, with an average return of -5.49% per trade.

1 Year

Mani ForooharLeerink Partners

Success Rate

35/47 ratings generated profit

Average Return

-2.17%

reiterated a sell rating 22 days ago

Copying Mani Foroohar's trades and holding each position for 1 Year would result in 74.47% of your transactions generating a profit, with an average return of -2.17% per trade.

2 Years

xxx

Success Rate

39/47 ratings generated profit

Average Return

+30.17%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 82.98% of your transactions generating a profit, with an average return of +30.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRNA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MRNA has received 6 Buy Ratings, 49 Hold Ratings, and 8 Sell Ratings. MRNA average Analyst price target in the past 3 months is 38.65.

Each month's total comprises the sum of three months' worth of ratings.

MRNA Financial Forecast

MRNA Earnings Forecast

Next quarter’s earnings estimate for MRNA is -$2.63 with a range of -$3.10 to -$1.93. The previous quarter’s EPS was -$0.51. MRNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Sales Forecast

Next quarter’s sales forecast for MRNA is $666.54M with a range of $540.00M to $924.83M. The previous quarter’s sales results were $1.02B. MRNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MRNA has Performed in-line its overall industry.

MRNA Stock Forecast FAQ

What is MRNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Moderna’s 12-month average price target is 38.65.

What is MRNA’s upside potential, based on the analysts’ average price target?

Moderna has 30.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MRNA a Buy, Sell or Hold?

Moderna has a consensus rating of Hold which is based on 3 buy ratings, 13 hold ratings and 4 sell ratings.

What is Moderna’s price target?

The average price target for Moderna is 38.65. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $198.00 ,the lowest forecast is $17.00. The average price target represents 30.44% Increase from the current price of $29.63.

What do analysts say about Moderna?

Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of MRNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Moderna (MRNA) Stock Forecast & Price Target

MRNA Analyst Ratings

MRNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Moderna

MRNA Analyst Recommendation Trends

MRNA Financial Forecast

MRNA Earnings Forecast

MRNA Sales Forecast

MRNA Stock Forecast FAQ

Detailed List of Analyst Forecasts